IRIS Institutional Research Information System - OPENBS Open Archive UniBS

RUSNATI, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.751
EU - Europa 8.305
AS - Asia 7.801
SA - Sud America 1.375
Continente sconosciuto - Info sul continente non disponibili 449
AF - Africa 186
OC - Oceania 43
Totale 33.910
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.466
PL - Polonia 3.414
CN - Cina 2.667
SG - Singapore 2.645
UA - Ucraina 1.299
BR - Brasile 1.148
HK - Hong Kong 829
IT - Italia 807
DE - Germania 764
VN - Vietnam 559
FI - Finlandia 451
GB - Regno Unito 381
FR - Francia 378
TR - Turchia 262
IN - India 233
RU - Federazione Russa 231
IE - Irlanda 221
BD - Bangladesh 177
CA - Canada 150
AR - Argentina 83
ID - Indonesia 79
MX - Messico 75
NL - Olanda 74
ZA - Sudafrica 66
IQ - Iraq 60
CZ - Repubblica Ceca 51
JP - Giappone 51
SE - Svezia 48
AU - Australia 41
EC - Ecuador 37
AT - Austria 36
ES - Italia 36
PK - Pakistan 34
MA - Marocco 30
BE - Belgio 26
CO - Colombia 26
KE - Kenya 25
UZ - Uzbekistan 24
CL - Cile 23
IR - Iran 22
JM - Giamaica 20
SA - Arabia Saudita 20
VE - Venezuela 20
JO - Giordania 16
AE - Emirati Arabi Uniti 15
CH - Svizzera 14
EU - Europa 14
AZ - Azerbaigian 13
IL - Israele 13
LT - Lituania 13
PE - Perù 13
KZ - Kazakistan 12
NG - Nigeria 12
EG - Egitto 11
MU - Mauritius 9
MY - Malesia 9
PY - Paraguay 9
UY - Uruguay 9
PA - Panama 8
BG - Bulgaria 7
DZ - Algeria 7
PT - Portogallo 7
TN - Tunisia 7
EE - Estonia 6
KR - Corea 6
LK - Sri Lanka 6
NP - Nepal 6
OM - Oman 6
BO - Bolivia 5
HN - Honduras 5
KG - Kirghizistan 5
LB - Libano 5
LV - Lettonia 5
SN - Senegal 5
TH - Thailandia 5
TT - Trinidad e Tobago 5
CR - Costa Rica 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
GT - Guatemala 4
NO - Norvegia 4
TW - Taiwan 4
AL - Albania 3
CY - Cipro 3
ET - Etiopia 3
GR - Grecia 3
HU - Ungheria 3
MD - Moldavia 3
PH - Filippine 3
PS - Palestinian Territory 3
RO - Romania 3
SI - Slovenia 3
AM - Armenia 2
AO - Angola 2
BB - Barbados 2
BH - Bahrain 2
GF - Guiana Francese 2
IS - Islanda 2
SV - El Salvador 2
ZW - Zimbabwe 2
Totale 33.447
Salva come PNG Salva come JPEG
Città #
Warsaw 3.405
Fairfield 1.667
Ashburn 1.345
Woodbridge 1.275
Singapore 1.243
Jacksonville 957
Houston 900
Hong Kong 826
Cambridge 712
San Jose 653
Ann Arbor 605
Wilmington 600
Seattle 581
Beijing 570
Chandler 503
The Dalles 449
Princeton 397
Nanjing 348
New York 317
Council Bluffs 310
Dallas 304
Helsinki 244
Los Angeles 244
Dublin 215
Lauterbourg 204
Columbus 198
Istanbul 186
Dearborn 154
Ho Chi Minh City 151
Brescia 149
Nanchang 125
Dong Ket 122
Munich 114
São Paulo 114
Milan 113
Buffalo 100
Moscow 98
Hanoi 97
San Francisco 93
Santa Clara 90
San Diego 88
Des Moines 86
Chicago 84
Shenyang 84
Jinan 82
Changsha 80
Hebei 74
Boardman 73
Redondo Beach 70
Tianjin 68
Phoenix 66
Jiaxing 65
Lancaster 63
Shanghai 63
London 62
Orem 59
Brooklyn 53
Hangzhou 53
Atlanta 46
Jakarta 46
Kunming 46
Tokyo 44
Toronto 44
Rome 42
Verona 40
Johannesburg 36
Guangzhou 35
Montreal 34
Rio de Janeiro 34
Augusta 32
San Mateo 32
Porto Alegre 31
Belo Horizonte 30
Chennai 30
Manchester 30
Denver 29
Zhengzhou 29
Frankfurt am Main 28
Nuremberg 28
Turku 28
Brno 27
Haikou 27
Lanzhou 27
Ningbo 26
Leawood 25
Amsterdam 24
Kocaeli 24
Mexico City 24
Brussels 23
Charlotte 22
Norwalk 22
Parma 22
Poplar 22
Curitiba 21
Mumbai 21
Nairobi 21
Olomouc 21
Dhaka 20
Tashkent 20
Vancouver 20
Totale 23.284
Salva come PNG Salva come JPEG
Nome #
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. 404
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Epheephrin system 383
Bridging the past and the future of virology: Surface plasmon resonance as a powerful tool to investigate virus/host interactions. 368
Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists. 320
Heparin/Heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutical use 320
Membrane association of peroxiredoxin-2 in red cells is mediated by n-terminal cytoplasmic domain of band 3 316
BSA conjugates bearing multiple copies of the basic domain of HIV-1 Tat: prototype for the development of multitarget inhibitors of extracellular Tat 315
Biological role of immunoglobulin Free light chains interactomes 313
Blocking the FGF/FGFR system as a "two-compartment" antiangiogenic/antitumor approach in cancer therapy. 308
Activation of Hsp90 Enzymatic Activity and Conformational Dynamics through Rationally Designed Allosteric Ligands 294
Highly Sulfated K5 Escherichia coli Polysaccharide Derivatives Inhibit Respiratory Syncytial Virus Infectivity in Cell Lines and Human Tracheal-Bronchial Histocultures. 291
Speeding Up the Identification of Cystic Fibrosis Transmembrane Conductance Regulator-Targeted Drugs: An Approach Based on Bioinformatics Strategies and Surface Plasmon Resonance 285
Different effects of mucosal, beef lung, and chemically modified heparin on selected biological properties of basic fibroblast growth factor 282
Heparan Sulfate Proteoglycans Mediate the Angiogenic Activity of the Vascular Endothelial Growth Factor Receptor-2 Agonist Gremlin. 282
Interaction of fibroblast growth factor-2 (FGF-2) with free gangliosides: biochemical characterization and biological consequences in endothelial cell cultures. 282
Angiogenic growth factors interactome and drug discovery: The contribution of surface plasmon resonance 282
Chemically sulfated Escherichia coli K5 polysaccharide derivatives as extracellular HIV-1 Tat protein antagonists. 276
Ruolo dell’eparina e dei proteoglicani eparan solfati nella modulazione dell’angiogenesi indotta dal fattore di crescita basico dei fibroblasti 276
Pradamicin A: a new therapeutic concept for tretment of virus infections with a glycosilated envelope such as human immunodeficiency virus 267
Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors 262
Inhibition of Non Canonical HIV-1 Tat Secretion Through the Cellular Na+,K+-ATPase Blocks HIV-1 Infection 261
In silico drug repositioning on F508del-CFTR: A proof-of-concept study on the AIFA library 258
UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice 251
A complex of α(6) integrin and E-cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietin-like 6. 249
Role of the soluble pattern recognition receptor PTX3 in vascular biology. 249
The AGMA1 poly(amidoamine) inhibits the infectivity of herpes simplex virus in cell lines, in human cervicovaginal histocultures, and in vaginally infected mice 247
The FGF2-binding domain of thrombospondin-1: functional characterization and exploitation to design antiangiogenic compounds 245
Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. 242
Chemoselective surface immbolization of proteins through a cleavable peptide 234
Functionalization of gold surfaces with copoly(DMA-NAS-MAPS) by dip coating: Surface characterization and hybridization tests 233
Sialic acid associated to αvβ3 integrin mediates HIV-1 Tat interaction and endothelial cell proangiogenic activation. 232
Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of HIV-1 Tat and gp120 proteins 231
The agmatine-containing poly(Amidoamine) polymer AGMA1 binds cell surface heparan sulfates and prevents attachment of mucosal human papillomaviruses 223
Integrin {alpha}V{beta}3 as a Target for Blocking HIV-1 Tat-Induced Endothelial Cell Activation In Vitro and Angiogenesis In Vivo. 222
Molecular Interaction Studies of HIV-1 Matrix Protein p17 and Heparin: IDENTIFICATION OF THE HEPARIN-BINDING MOTIF OF p17 AS A TARGET FOR THE DEVELOPMENT OF MULTITARGET ANTAGONISTS 220
A distinct basic fibroblast growth factor (FGF-2/FGF receptor interaction distinguishes urokinase-type plasminogen activator induction from mitogenicity in endothelial cells 210
Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts. 209
Fibroblast growth factor-2 antagonist and Antiangiogenic activity of long-pentraxin 3-derived synthetic peptides 206
A CXCR1 haplotype hampers HIV-1 matrix protein p17 biological activity 204
Critical role of gonadal hormones on the genotoxic activity of the hepatocarcinogen DL-ZAMI 1305. 203
A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: Implications for EBV-driven lymphomagenesis in the HIV setting. 202
Biologically active synthetic fragments of human basic fibroblast growth factor (bFGF): identification of two Asp-Gly-Arg-containing domains involved in the mitogenic activity of bFGF in endothelial cells. 198
Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium. A study of aortic and microvascular endothelial cell lines. 198
alphav/beta3 Integrin mediates the cell-adhesive capacity and biological activity of basic fibroblast growth factor (FGF2) in cultured endothelial cells 194
Merging colloidal nanoplasmonics and surface plasmon resonance spectroscopy for enhanced profiling of multiple myeloma-derived exosomes 192
The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. 191
Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form. 189
Contribution of vascular endothelial growth factor receptor-2 sialylation to the process of angiogenesis 188
Exploitation of a novel biosensor based on the full-length human F508del-CFTR with computational studies, biochemical and biological assays for the characterization of a new Lumacaftor/Tezacaftor analogue 188
Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach 185
Basic fibroblast growth factor requires a long-lasting activation of protein kinase C to induce cell proliferation in transformed fetal bovine aortic endothelial cells. 183
Alterations of blood vessel development by endothelial cells overexpressing fibroblast growth factor-2 180
A six-amino acid deletion in basic fibroblast growth factor dissociates its mitogenic activity from its plasminogen activator-inducing capacity. 178
Examining new models for the study of autocrine and paracrine mechanisms of angiogenesis through FGF2-transfected endothelial and tumour cells. 178
Sialic acid as a target for the development of novel antiangiogenic strategies 177
A mutant of basic fibroblast growth factor that has lost the ability to stimulate plasminogen activator synthesis in endothelial cells. 173
Heparin and heparan sulfate proteoglycans promote HIV-1 p17 matrix protein oligomerization: computational, biochemical and biological implications 172
Upregulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx 169
Basic fibroblast growth factor expression in endothelial cells: an autocrine role in angiogenesis? 168
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 168
Subcellular localization and biological activity of a Mr 18,000 basic fibroblast growth factor: site directed mutagenesis of a putative nuclear translocation sequence 163
Autocrine role of basic fibroblast growth factor (bFGF) in angiogenesis and angioproliferative diseases 163
HIV-1 matrix protein p17 binds to the IL-8 receptor CXCR1 and shows IL-8-like chemokine activity on monocytes through Rho/ROCK activation 163
The colloidal side of cell communication. 163
Surface functionalization of extracellular vesicle nanoparticles with antibodies: a first study on the protein corona "variable" 160
Cutting edge: proangiogenic properties of alternatively activated dendritic cells. 160
Simian immunodeficiency virus and human immunodeficiency virus type 1 matrix proteins specify different capabilities to modulate B cell growth. 159
Distinct role of 2-O, N-, and 6-O-sulfate groups of heparin in the formation of the ternary complex with basic fibroblast growth factor and soluble FGF receptor-1 159
Basic fibroblast growth factor in ovulatory cycle and postmenopausal human endometrium. 157
Human basic fibroblast growth factor: structure- function relationship of an angiogenic molecule 157
Syndecan-1 increases B-lymphoid cell extravasation in response to HIV-1 Tat via αvβ3/pp60src/pp125FAK pathway 154
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 154
Interaction of fibroblast growth factor-2 (FGF-2) with free gangliosides: biochemical characterization and biological consequences in endothelial cell cultures 151
Cell membrane GM1 ganglioside is a functional co-receptor for Fibroblast growth factor-2. 151
alpha v beta 3 integrin-dependent activation of focal adhesion kinase mediates NF-kB activation and motogenic activity by HIV-1 Tat in endothelial cells 150
Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity 149
Purification of basic fibroblast growth factor from rat brain: identification of a Mr 22,000 immunoreactive form. 149
The calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2) 149
Multiple interactions of HIV-1 Tat protein with size-defined heparin oligosaccharides 148
A monoclonal antibody to the NH2-terminal region of HuIFN inhibits the antiproliferative activity of the lymphokine without affecting its internalization 148
Biochemical bases of the interaction of the human basic fibroblast growth factor with glycosaminoglycans: new insights from trypsin digestion studies 148
Discovery of novel FGF trap small molecules endowed with anti-myeloma activity 147
Plasmonic exosomes for enhanced monitoring of monoclonal gammopathies 147
Fibroblast growth factor-2 in angiogenesis 146
HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2 146
Structure-function relationship of basic fibroblast growth factor: site-directed mutagenesis of a putative heparin-binding and receptor-binding region. 141
Heparin derivatives as angiogenesis inhibitors 140
Dendritic cell-endothelial cell cross-talk in angiogenesis. 140
Liver DNA damage by chemical carcinogens: role of thyroid hormones 140
Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors. 138
Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases 138
Polysulfated/sulfonated compounds for the development of drugs at the crossroad of viral infection and oncogenesis 137
Fibroblast growth factors and their receptors in hematopoiesis and hematological tumors 137
Targeting fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis 136
Multispot, label-free biodetection at a phantom plastic-water interface. 136
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction 136
Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds 135
Urokinase-type plasminogen activator overexpression enhances the invasive capacity of endothelial cells. 135
The Impact of Surface Plasmon Resonance in Virology 135
Internalization of HIV-1 Tat requires cell surface heparan sulfate proteoglycans 134
Totale 20.325
Salva come PNG Salva come JPEG
Categoria #
all - tutte 143.977
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 143.977
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.692 0 423 30 43 24 69 123 119 84 235 141 401
2022/20231.409 219 59 56 93 106 382 9 149 198 18 48 72
2023/20241.549 93 30 137 68 67 235 52 69 403 49 40 306
2024/20253.988 47 23 18 493 356 286 279 125 350 461 948 602
2025/20268.982 824 1.167 829 1.315 805 602 1.301 317 579 736 268 239
2026/2027854 391 463 0 0 0 0 0 0 0 0 0 0
Totale 33.910